BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines. The company, incorporated in Delaware in August 1933 as Bristol-Myers Company and renamed in 1989 after a merger, operates in a single segment. Its strategy combines the resources of a large pharmaceutical company with the agility of the biotech industry. Bristol-Myers Squibb focuses on delivering transformational medicines for patients with serious diseases in oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company prioritizes transformational medicines where it has a competitive advantage, operational excellence, and strategic capital allocation for growth and shareholder returns. It drives commercial execution in key first-in-class and/or best-in-class marketed products. Bristol-Myers Squibb competes with global research-based drug companies, smaller research companies, and generic drug manufacturers. Its products are sold worldwide, primarily to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, government agencies, and directly to patients. The company has significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland, and Switzerland.